NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The company is located in Woburn, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. NeuroMetrix markets the following products: DPNCheck® is an automated, fast, accurate, and quantitative nerve conduction test used to evaluate peripheral neuropathies. It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor peripheral neuropathies. Please visit at www.dpncheck.com. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Please visit www.advancencs.com. Quell® is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. The Company is also developing prescription applications using the Quell technology platform. Please visit www.QuellRelief.com.
$3.5M sweet spot round size
1996
$3.5M
from investors over 1 rounds
NeuroMetrix, Inc. raised $3.5M on December 1, 2017